Telomir Pharmaceuticals Inc TELO Q4 2025 Earnings Wider Than Expected Loss Highlights PreRevenue Challenges OSBC Q1 2026 Earnings Earnings Miss but Stable Share Price CEVA Q1 2026 Earnings EPS Surges Past Estimates Stock Declines Despite Beat ACAD Q1 2026 Earnings Mixed Results as EPS Misses Estimates OMC Q1 2026 Earnings EPS Surpasses Estimates Amid Mixed Market Dynamics CISS Q3 2025 Earnings Losses Widen as Stock Declines 512